Alacer Gold opens 4% higher in response to solid 2016 production and robust guidance for 2017

Published 18-JAN-2017 15:26 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Alacer Gold is located in Turkey, a region which currently carries high sovereign risk. Those considering this stock as an investment should take this very high risk environment into account and seek independent financial advice for further information.

Alacer Gold Corporation (ASX: AQG) has achieved its best quarter of production for 2016 from the Copler gold project located in Turkey. The company announced its 2016 Results and Increased Production Guidance, which showed that in three months to December 31, 2016 AQG produced 33,800 ounces of gold, well above the previous quarter when production was 23,200 ounces.

This resulted in the company achieving full-year production of approximately 119,000 ounces, at the midpoint of December guidance which was in a range between 115,000 ounces and 125,000 ounces.

However, what may come as a surprise is the 2017 production guidance which is in a range between 160,000 ounces and 180,000 ounces. Analysts at Macquarie revised their figures in December and were forecasting production of 93,000 ounces in 2016, increasing to 121,700 ounces in 2017.

Alacer finished in a strong financial position being debt free and having a cash balance of $215 million.

In discussing the year ahead, Chief Executive Rod Antal said, “In addition to the higher gold production, 2017 will be a pivotal year for Alacer as we continue to execute on our organic growth strategy”.

On this note, the group will advance construction of the Copler sulphide expansion project, which is on schedule for maiden gold production in 2018.

Management also hasn’t discounted the prospect of acquisitions to complement the Copler project as it strives to become a sustainable multi-mine producer with a focus on Turkey.

It should be noted, however, that any further catalysts are speculative at this stage and should not be taken as guaranteed. Investors should seek professional financial advice for further information.

tags

GOLD


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X